Articles On Cynata Therapeutics (ASX:CYP)

Cynata preparing for two trial readouts in 2026 in knee osteoarthritis and acute graft-versus-host disease  2025 considered a transitional year for stem cell and regenerative medicine company  Cynata’s proprietary Cymerus platform overcome...

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

ASX gains 23 points or 0.27% in choppy session of trade Real estate plunges 2.11% while banks and resources make strong gains Bond yields climb to highest level in 2025 on rate hike fears   ASX rides commodity wave higher The ASX 200 adde...

A global study links Alzheimer’s disease with kidney malfunction FDA czar Dr Marty Makary outlines the agency’s priorities Pro Medicus fesses up to a cyber breach   The quest for an Alzheimer’s disease cure has taken a new twist, with an...

Review of first cohort in Cynata’s phase 1/2 NEREID trial in kidney transplant patients successfully completed No safety concerns identified with trial cleared to progress to the next stage Trial managed and funded by global kidney transp...

ASX stumbles as announcement outage leaves traders scrambling to catch up Gold and oil climb, providing some support in energy and resource stocks Wall Street futures weigh heavy; market falls 0.57% ASX scrambles to address announcement b...

ASX powers higher in fresh trading week, up 1.29pc Defensive sectors lead gains with strong support from gold index Energy was the only sector in the red as crude prices fall   Strong start to trading week The ASX 200 has had a strong sta...

Final patient visit completed in Cynata Therapeutics’ Phase III SCUlpTOR trial evaluating CYP-004 in knee osteoarthritis Trial is being conducted by the University of Sydney, which will now finalise quality-control checks before commencin...

Ahead of EBR Systems’ official Wise launch in the US, clinicians already have implanted a dozen patients with the heart device Renerve shares more than double on key US nerve repair military approval   Cynata enters “the most important” ch...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode, Tim catches up with Cynata Therapeutics (ASX:CYP) CEO Dr Kilian Kelly to dive into the stem cell ind...

Highlights Duratec and Lovisa identified among undervalued Australian equities. Broader ASX landscape shows resilience amid market diversity. Infrastructure, retail, and technology sectors feature strong value cases. A...

Highlights Undervalued ASX stocks gaining attention across multiple sectors Electro Optic Systems and James Hardie lead the undervaluation list Broader outlook reveals opportunities within the Australian equity landscape...

Highlights Australian market steadies amid global shifts. Emerging undervalued companies gain investor attention. Technology and healthcare sectors lead potential recovery. Australian equities spotlight undervalued opp...

Mesenchymal stromal cells (MSCs) have long been regarded as one of nature’s most powerful repair systems—cells with the ability to reduce inflammation, regulate immune responses and stimulate tissue healing. For decades, they have been seen...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

Perversely, Polynovo stands to benefit from a US reimbursement cut for outpatients ASX biotechs had a poor August, but they will Spring into action Race Oncology opens Hong Kong site in “cautious” trial rollout   PolyNovo (ASX:PNV) shares...

Neuren’s US partner Acadia reports a 14% sales boost Look out for a slew of advanced clinical trial results in early 2026 IDT Australia shares plunge up to 39% after CEO departs “with immediate effect”   Despite firming US sales of its Re...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

ASX surges 1.37pc, smashing through record to close at 8757 points All 11 sectors neon green, up between 2.47pc and 0.46pc Healthcare and resources stocks crank higher, leading gains DJ play it louder It was a raver of a party on the ASX...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Highlights Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with limited treatment options. AdAlta, Cynata, and Amplia are advancing innovative therapeutic approaches. Australian biotechnology companies are expanding...

Idiopathic pulmonary fibrosis is a life-threatening lung disease AdAlta’s lead candidate AD-214 is a first-in-class molecule designed to treat IPF Amplia and Cynata therapies also show promise in treating the disease, which has limited tre...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Like London buses, takeovers tend to come in a rush Mayne Pharma had struggled for years, but its performance was improving Takeovers in the ASX biotech sector have been few and far between The ‘London’ Bus theory goes that if one takeove...

Cynata Therapeutics (ASX:CYP) has had its induced pluripotent stem cell (iPSC) derived mesenchymal stem cell (MSCs) verified as similar to convention MSCs in a study published in a peer-review journal. MSCs are what most people think of...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

Sonic Healthcare to buy LADR – Laboratory Group Dr. Kramer & Colleagues in Germany for ~A$700 million ASX health stocks fall 2.3% over past five days, while the broader market fell ~1.5%  Chemist Warehouse could list on the ASX by earl...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin MELBOURNE, Australia, Dec. 5, 2024 /PRNewswire/ — Cynata Therapeutics Limited (ASX:...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

ASX healthcare stocks underperform but optimism grows Uscom, Respiri and Hitiq report mixed results Artrya and Nyrada make key clinical advances   The S&P/ASX 200 Health Care [XHJ] index was down 0.9% gain in October. For the year, th...

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Cynata Therapeutics flags three trial results in the short term for three different conditions, including diabetic leg ulcers Prescient Therapeutics prepares for a blood cancer trial and potential fast-track approval Pacific Edge chairman...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

Volatility remained the status quo as the ASX200 ended down 0.23%. The local bourse briefly touched into the green after lunch, but the mood was short-lived. The market almost immediately pared gains, sinking back into the red. There...

The ASX dropped, dragged down by Real Estate and Mining stocks Qantas cuts former CEO’s compensation by $9.3m Fears of a US recession are growing, with the Sahm Rule signalling potential trouble   A selloff in Real Estate and Mining stock...

Cynata Therapeutics Ltd (ASX:CYP) has seen its share price rise more than 10% on the release of a study indicating the potential for Cymerus – its ‘off the shelf’ therapeutic stem cell platform technology – to reverse pulmonary fibrosis and...

  To register for Friday's webinar click here. NOVONIX (ASX:NVX) and CBMM has joined forces to develop cost-effective, high-performance cathode materials. NOVONIX's patented process will combine with CBMM's niobium to create high-performanc...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

Imricor completes installation of iCMR capital equipment at Lausanne University Hospital in Switzerland PYC Therapeutics says safety data from patient cohort four successfully reviewed with recommendation trial continues Cynata Therapeutic...

ASX rose  as the RBA held interest rates at 12-year high 4.35pc All 11 sectors on the ASX gained, with significant moves from Pilbara and Fortescue  ASX to launch first bitcoin-linked ETF on Thursday   Aussie stocks bounced back by +0.8%...

 S&P/ASX 200 Health Care closed flat in May 2024 brings challenges, but hopes are high for biotech stocks We take a look at the ASX biotech winners for the month   The  S&P/ASX 200 Health Care [XHJ] closed flattish for the month o...

Research shows Alzheimer’s is entirely preventable A poor diet and bad gut bacteria can increase the risk of dementia We look at the best performing ASX stocks over the past month    The phrase ‘you are what you eat’ was coined almost a c...

Special Report: A recent lunch put together in Sydney by Jane Morgan Management and Éthica Capital saw a number of the ASX’s most innovative biotech and tech companies present and pitch to an audience of potential investors on the lookout f...

Momentum trading involves taking advantage of, and making profits from, upward trends in a stock. The strategy makes a calculated bet that the stock market’s recent winners will remain winners. The Relative Strength Index (RSI) is a popular...

Investors got the chance to get up close and personal with ASX technology and biotech companies in Sydney recently at the JMM & Ethica Capital Innovation & Investment Insights Lunch. Featuring quick ‘stand up and pitch your story’ s...